Can Lupus Cause Candidiasis?
Yes, systemic lupus erythematosus (SLE) significantly predisposes patients to candidiasis, primarily through disease-related immunosuppression and immunosuppressive medications, rather than through the disease itself. The risk is particularly elevated in patients receiving glucocorticoids and other immunosuppressive therapies 1.
Mechanisms of Increased Susceptibility
The heightened infection risk in SLE patients stems from multiple factors:
Immunosuppressive therapy is the primary driver, particularly moderate-to-high dose corticosteroids, cyclophosphamide, mycophenolate mofetil, and azathioprine, which impair immune responses to fungal pathogens 2.
Intrinsic immune dysfunction in SLE includes low complement levels, functional asplenia, and abnormal neutrophil and macrophage responses 2.
Severe lymphopenia (≤500 cells/mm³) and low IgG levels (≤500 mg/dL) are specific risk factors that should be monitored, as they correlate with increased infection susceptibility 1.
Clinical Context and Risk Stratification
Patients with profound immunosuppression are at highest risk for mucocutaneous candidiasis, including oropharyngeal, esophageal, and vulvovaginal forms 3. The risk parallels that seen in other immunosuppressed populations, such as HIV/AIDS patients on high-dose corticosteroids 3.
Key monitoring parameters include:
- Severe neutropenia (<500 cells/mm³)
- Severe lymphopenia (<500 cells/mm³)
- Low IgG (<500 mg/dL) or specific subclass deficiencies (IgG3 ≤60 μg/mL or IgG4 ≤20 μg/mL) 1.
Practical Management Considerations
Screen for candidiasis risk factors at baseline and during follow-up, particularly when initiating or escalating immunosuppressive therapy 1. While SLE patients do not have increased baseline rates of HIV, HBV, or HCV infection compared to the general population, screening is recommended before starting immunosuppression due to reactivation risks 1.
CMV testing should be considered during high-dose corticosteroid therapy (18-44% antigenaemia rate), as CMV infection can mimic active SLE and complicate the clinical picture 1.
Important Caveats
The provided evidence focuses primarily on HIV-related candidiasis guidelines 3, 4 and general SLE infection monitoring 1. While these establish that profound immunosuppression predisposes to candidiasis, direct epidemiological data on candidiasis incidence specifically in SLE populations is limited in the available evidence. However, the mechanistic overlap—particularly with high-dose glucocorticoid use—makes the association clinically relevant and well-established in practice.
Assess immunosuppression burden continuously rather than assuming static risk, as infection susceptibility correlates with cumulative immunosuppressive exposure and current disease activity 1.